Under construction – not a live service
Sign in
Taking people in United KingdomNo phase

Testing a new visual field device against the standard machine in glaucoma

Compares a new field-of-vision testing device with the standard machine in glaucoma patients.

Plain-language title generated from the registry record
Registry title: World Sight Foundation Field Machine (WSFFM) Pilot

Key facts

Where
Aylesbury, United KingdomSee the site

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 99 years old?

Source: NCT07674069, who can take part

Where in United Kingdom

  • Buckinghamshire Healthcare NHS TrustAylesbury, United KingdomTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Buckinghamshire Healthcare NHS Trust
Trial code
NCT07674069
Record updated
29 June 2026
Original description
The current situation outside of large cities in lower-income countries, as described above, is suboptimal for the diagnosis of glaucoma. Doctors have no means of assessing visual fields, and as such may not be able to identify the condition until too advanced for any meaningful intervention (ie, to enable preservation of vision). Vision loss from glaucoma is irreversible. Understanding, through this pilot study, how well the World Sight Foundation Field Machine (WSFFM) works is an essential step towards trialling its use in lower-income countries. The justification for enabling this is to allow clinicians in the developing world to make more informed assessments of their glaucoma patient's status; this should translate in more timely treatments or referral for further investigation before further irreversible vision loss.Read full original descriptionShow less

Clinical Testing Pilot of the World Sight Foundation Field Machine (WSFFM) in Glaucoma Patients - Comparison With Humphrey Visual Field Analyser

The current situation outside of large cities in lower-income countries, as described above, is suboptimal for the diagnosis of glaucoma. Doctors have no means of assessing visual fields, and as such may not be able to identify the condition until too advanced for any meaningful intervention (ie, to enable preservation of vision). Vision loss from glaucoma is irreversible. Understanding, through this pilot study, how well the World Sight Foundation Field Machine (WSFFM) works is an essential step towards trialling its use in lower-income countries. The justification for enabling this is to allow clinicians in the developing world to make more informed assessments of their glaucoma patient's status; this should translate in more timely treatments or referral for further investigation before further irreversible vision loss.

The WSFFM will be compared to the Humphrey Visual Field (HVF) analyser. The HVF analyser is the gold standard method of measuring visual fields; in our hospital eye service it is almost exclusively the method used, and as such the field technicians are particularly skilled in their use. The output data of the HVF enables easy quantification of level of field loss; by comparing the output from the WSFFM it would be possible to allow some form of quantification against "the standard" such that an idea of how well it works may be calculated.

Inclusion: - Patients attending glaucoma outpatient clinic; Patients requiring visual field testing, with plan for "SITA-STANDARD" HVF testing; Patients 18 years or older and of any gender; Patients capable of giving informed consent.

Exclusion: Patients under the age of 18 years old; - Patients not requiring visual field testing on that outpatient clinic attendance; Patients requiring visual field testing, with plan for "SITA-FAST" or "SITA-FASTER" HVF testing; Patients who do not attend their outpatient clinic appointment,; Patients not able to perform visual field testing (for example due to their visual acuity, physical difficulty in positioning for test duration, or cognitive difficulties in understanding instructions).

ClinicalTrials.gov NCT07674069